Delivery of recombinant bone morphogenetic proteins for bone regeneration and repair. Part A: Current challenges in BMP delivery.
Recombinant human bone morphogenetic proteins (rhBMPs) have been extensively investigated for developing therapeutic strategies aimed at the restoration and treatment of orthopaedic as well as craniofacial conditions. In this first part of the review, we discuss the rationale for the necessary use of carrier systems to deliver rhBMP-2 and rhBMP-7 to sites of bone tissue regeneration and repair. General requirements for growth factor delivery systems emphasizing the distinction between localized and release-controlled delivery strategies are presented highlighting the current limitations in the development of an effective rhBMP delivery system applicable in clinical bone tissue engineering.
Haidar
Ziyad S
ZS
Faculty of Dentistry, McGill University, 740 Rue Dr. Penfield Suite # 4300, Montréal, QC, H3A 1A4, Canada.
Hamdy
Reggie C
RC
Tabrizian
Maryam
M
D001847:Bone Diseases / Q000628:therapy*; D055396:Bone Morphogenetic Protein 2 / Q000235:genetics / Q000627:therapeutic use*; D055419:Bone Morphogenetic Protein 7 / Q000235:genetics / Q000627:therapeutic use*; D001861:Bone Regeneration / Q000502:physiology*; D019465:Craniofacial Abnormalities / Q000628:therapy*; D006801:Humans; D019637:Orthopedic Procedures / Q000379:methods*; D011994:Recombinant Proteins / Q000235:genetics / Q000627:therapeutic use*
C525718:BMP2 protein, human; D055396:Bone Morphogenetic Protein 2; D055419:Bone Morphogenetic Protein 7; D011994:Recombinant Proteins